Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday

Terns Pharmaceuticals (NASDAQ:TERN) is expected to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

Terns Pharmaceuticals Price Performance

TERN stock opened at $3.48 on Wednesday. The stock has a market capitalization of $295.59 million, a price-to-earnings ratio of -2.95 and a beta of -0.30. The business’s fifty day moving average price is $4.38 and its two-hundred day moving average price is $6.30. Terns Pharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $11.40.

Insider Activity at Terns Pharmaceuticals

In related news, CFO Mark J. Vignola sold 9,059 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $5.80, for a total value of $52,542.20. Following the sale, the chief financial officer now directly owns 74,752 shares of the company’s stock, valued at $433,561.60. This trade represents a 10.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jill M. Quigley sold 6,240 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.72, for a total value of $35,692.80. Following the completion of the sale, the director now directly owns 8,760 shares in the company, valued at $50,107.20. This trade represents a 41.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,669 shares of company stock valued at $211,040 over the last ninety days. 15.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TERN shares. William Blair started coverage on Terns Pharmaceuticals in a report on Friday, February 28th. They set a “market perform” rating on the stock. HC Wainwright reissued a “neutral” rating and set a $7.50 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. Oppenheimer increased their target price on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 4th. Finally, JMP Securities reissued a “market outperform” rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Terns Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.30.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.